Form 4: Boston Scientific EVP Wendy Carruthers Reports Stock Transactions

Wendy Carruthers, EVP of Human Resources at Boston Scientific, reports exercising stock options and selling shares under a pre-established Rule 10b5-1 trading plan.

Summary

• On July 1, 2024, Wendy Carruthers, EVP of Human Resources at Boston Scientific, executed transactions involving Boston Scientific common stock.
• Carruthers exercised stock options to acquire 3,066 shares at $17.26 and 1,197 shares at $24.55.
• She also sold 6,983 shares at $77.30.
• These transactions were conducted under a pre-established Rule 10b5-1 trading plan adopted on November 17, 2023.
• Following these transactions, Carruthers directly owns 42,908 shares of Boston Scientific common stock and holds options to purchase 34,498 more shares.

Sentiment

Score: 5

Explanation: The sentiment is neutral as this is a standard regulatory filing detailing stock transactions by an executive. There is no indication of positive or negative implications for the company's performance.

Industry Context

This Form 4 filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the trading activities of company executives.

Comparison to Industry Standards

• Insider trading activity is a common occurrence in publicly traded companies like Boston Scientific.
• Similar filings are regularly made by executives at comparable medical device companies such as Medtronic (MDT) and Abbott Laboratories (ABT).
• The use of Rule 10b5-1 trading plans is a standard practice to avoid accusations of trading on inside information.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the change in ownership, but the effect is likely minimal given the relatively small number of shares involved.
• There is no direct impact on employees, customers, suppliers, or creditors.

Key Dates